{"id":12820,"date":"2026-08-18T16:10:31","date_gmt":"2026-08-18T13:10:31","guid":{"rendered":"https:\/\/grindeks.com\/?p=12820"},"modified":"2026-08-18T16:29:29","modified_gmt":"2026-08-18T13:29:29","slug":"as-grindeks-apgrozijums-2025-gada-sasniedza-1109-miljonus-eiro","status":"publish","type":"post","link":"https:\/\/grindeks.com\/lv\/as-grindeks-apgrozijums-2025-gada-sasniedza-1109-miljonus-eiro\/","title":{"rendered":"AS \u201cGrindeks\u201d apgroz\u012bjums 2025. gad\u0101 sasniedza 110,9 miljonus eiro"},"content":{"rendered":"\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:100%\">\n<p class=\"has-text-align-left wp-block-paragraph\">AS \u201cGrindeks\u201d finan\u0161u dati liecina, ka 2025. gad\u0101 sabiedr\u012bbas apgroz\u012bjums sasniedza 110,9 miljonus eiro, kas ir par 4 % vair\u0101k nek\u0101 2024. gad\u0101. Savuk\u0101rt sabiedr\u012bbas pe\u013c\u0146a sasniedza 12,6 milj. eiro, gandr\u012bz piecas reizes p\u0101rsniedzot 2024. gada r\u0101d\u012bt\u0101ju. Rezult\u0101ti apliecina uz\u0146\u0113muma ilgtermi\u0146a att\u012bst\u012bbas strat\u0113\u0123ijas efektivit\u0101ti un m\u0113r\u0137tiec\u012bgos ieguld\u012bjumus produktu att\u012bst\u012bb\u0101, eksporta papla\u0161in\u0101\u0161an\u0101 un starptautisk\u0101s konkur\u0113tsp\u0113jas stiprin\u0101\u0161an\u0101.<\/p>\n<\/div>\n<\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><strong>AS \u201cGrindeks\u201d padomes priek\u0161s\u0113d\u0113t\u0101js Kirovs Lipmans uzsver: <\/strong><em>\u201cP\u0113d\u0113jo gadu laik\u0101 esam konsekventi invest\u0113ju\u0161i jaunu tirgu att\u012bst\u012bb\u0101, produktu re\u0123istr\u0101cij\u0101 un starptautisk\u0101s kl\u0101tb\u016btnes stiprin\u0101\u0161an\u0101. Vienlaikus esam p\u0101rskat\u012bju\u0161i koncerna strukt\u016bru, koncentr\u0113jot resursus uz biznesa virzieniem un tirgiem ar augst\u0101ko izaugsmes potenci\u0101lu un pievienoto v\u0113rt\u012bbu. \u0160odien redzam \u0161o ieguld\u012bjumu rezult\u0101tus \u2013 uz\u0146\u0113mums ir k\u013cuvis efekt\u012bv\u0101ks, konkur\u0113tsp\u0113j\u012bg\u0101ks un lab\u0101k sagatavots ilgtsp\u0113j\u012bgai izaugsmei.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\">2025. gad\u0101 uz\u0146\u0113muma izaugsmi veicin\u0101ja stabils piepras\u012bjums p\u0113c medikamentiem t\u0101 galvenaj\u0101s terapeitiskaj\u0101s jom\u0101s \u2013 sirds un asinsvadu, centr\u0101l\u0101s nervu sist\u0113mas, onkolo\u0123isko saslim\u0161anu un diab\u0113ta \u0101rst\u0113\u0161an\u0101.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p class=\"wp-block-paragraph\"><strong>AS \u201cGrindeks\u201d valdes priek\u0161s\u0113d\u0113t\u0101js J\u0101nis Romanovskis<\/strong><em> <\/em><strong>nor\u0101da:<\/strong><em> \u201c\u0122eopolitisk\u0101 situ\u0101cija ir b\u016btiski ietekm\u0113jusi farm\u0101cijas nozari \u2013 pieg\u0101\u017eu \u0137\u0113des, izejvielu cenas un z\u0101\u013cu pieejam\u012bba da\u017e\u0101dos tirgos. M\u016bsu priorit\u0101te ir nodro\u0161in\u0101t pacientiem nep\u0101rtrauktu piek\u013cuvi kvalitat\u012bviem medikamentiem, vienlaikus att\u012bstot produktu portfeli, stiprinot p\u0113tniec\u012bbu un att\u012bst\u012bbu, k\u0101 ar\u012b pilnveidojot ra\u017eo\u0161anas procesus. Tas \u013cauj saglab\u0101t uz\u0146\u0113muma konkur\u0113tsp\u0113ju un veidot ilgtsp\u0113j\u012bgu izaugsmi ar\u012b main\u012bgos tirgus apst\u0101k\u013cos\u201d.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u201cGrindeks\u201d att\u012bsta produktu portfeli<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cGrindeks\u201d produktu portfeli tuv\u0101kajos gados papildin\u0101s vair\u0101ki jauni medikamenti. \u0160obr\u012bd da\u017e\u0101dos izstr\u0101des posmos ir 28 produkti, savuk\u0101rt z\u0101\u013cu re\u0123istr\u0101cijas proced\u016bra ir uzs\u0101kta 12 patentbr\u012bvajiem medikamentiem.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cGrindeks\u201d gatavo z\u0101\u013cu p\u0101rdo\u0161anas apjoms 2025. gad\u0101 sasniedza 101,5 milj. eiro, kas ir par 4 % vair\u0101k nek\u0101 gadu iepriek\u0161.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Viena no b\u016btisk\u0101kaj\u0101m \u201cGrindeks\u201d konkurences priek\u0161roc\u012bb\u0101m ir akt\u012bvo farmaceitisko vielu izstr\u0101de un ra\u017eo\u0161ana. Tas stiprina uz\u0146\u0113muma neatkar\u012bbu no \u0101r\u0113jiem izejvielu pieg\u0101d\u0101t\u0101jiem un palielina pieg\u0101\u017eu \u0137\u0113des dro\u0161\u012bbu. Liel\u0101kie akt\u012bvo farmaceitisko vielu eksporta tirgi ir Eiropas Savien\u012bbas valstis, Jap\u0101na, Amerikas Savienot\u0101s Valstis un Austr\u0101lija.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pla\u0161\u0101kai inform\u0101cijai:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Marika \u016adre<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AS \u201cGrindeks\u201d Komunik\u0101cijas un sabiedrisko attiec\u012bbu vad\u012bt\u0101ja<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tel.: +371 27277629<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">E-pasts: marika.udre@grindeks.com<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AS \u201cGrindeks\u201d finan\u0161u dati liecina, ka 2025. gad\u0101 sabiedr\u012bbas apgroz\u012bjums sasniedza 110,9 miljonus eiro, kas ir par 4 % vair\u0101k nek\u0101 2024. gad\u0101. Savuk\u0101rt sabiedr\u012bbas&#8230;<\/p>\n","protected":false},"author":22,"featured_media":12847,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2,1],"tags":[],"class_list":["post-12820","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums","category-news"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/12820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/22"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=12820"}],"version-history":[{"count":6,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/12820\/revisions"}],"predecessor-version":[{"id":12830,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/12820\/revisions\/12830"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/12847"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=12820"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=12820"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=12820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}